Novartis teams up with Oxford researchers to crunch big data into clinical insights

Since Vas Narasimhan’s Day 1 as CEO of Novartis, he has championed data science and digital technologies as a key priority at the pharma giant. Almost a year into his tenure, in a recent conversation with the tech VC firm Andreessen Horowitz, he highlighted the abilities to analyze pathology images and centralize clinical trial planning as two promising applications of machine learning.